Health Technology Assessment Workshop

HEALTH TECHNOLOGY ASSESSMENT WORKSHOP

Sponsored by bluebird bio

Mock Technology Appraisal for Regenerative Medicine: Perspectives from U.S. and EU Health Technology Assessment (HTA) Experts

As a follow-up to the October 5th Technology Assessment Panel, this workshop will take a deeper dive into the challenges HTAs will face when assessing a one-time, potentially transformative therapy. Participants will include experts in HTA from both the U.S. and EU. To stimulate critical thinking, an ‘exemplar’ case study incorporating a hypothetical product will be developed and provided to panel members for their consideration in advance of the meeting. The case study will include target indication and population, a brief summary of current standard of care and what is known about likely comparators, expected evidence generated from trial program and other supporting data. Panel members will present their initial assessment of the product based on the value framework they typically apply. Their feedback is expected to encompass:

Strengths and weaknesses of existing evidence base
Applicability of comparators
Key areas of uncertainty as related to value demonstration
The workshop will then involve participant and audience feedback on creative approaches to fill the identified gaps.

Chair:
Doug Danison, VP Access, Value and Evidence Strategy, bluebird bio

Speakers:
Jim Cross, M.D., Former VP, National Medical Policy and Operations, Aetna; President, Jim Cross, MD Consulting
Bill Dreitlein, Pharm.D., Director of Pharmaceutical Policy, Institute for Clinical and Economic Review (ICER)
Clark Paramore, Head of Value Demonstration, bluebird bio
Keith Tolley, Director, Tolley Health Economics

Видео Health Technology Assessment Workshop канала Alliance for Regenerative Medicine